Cassava Sciences

Yahoo Finance • 4 days ago

Cassava Sciences rises 10% after market close on CEO stock buy

[bull market buying - green stock data trading screen] bunhill * Cassava Sciences has popped 10% in after-market-close trading Monday following an SEC filing indicated that CEO Richard Barry acquired a large number of shares on Nov. 20... Full story

Yahoo Finance • last month

Cassava says court dismisses criminal case against scientist

Cassava Sciences (NASDAQ:SAVA [https://seekingalpha.com/symbol/SAVA]) shares rose as much as 6% premarket on Friday after a U.S. court dismissed [https://seekingalpha.com/filing/10556365]a criminal case against Hoau-Yan Wang, a former scie... Full story

Yahoo Finance • last month

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders... Full story

Yahoo Finance • 2 months ago

Spotlight On Top Penny Stocks In September 2025

As of late September 2025, the U.S. stock market has experienced a downturn, with major indices such as the Dow Jones Industrial Average, S&P 500, and Nasdaq closing lower due to declines in tech stocks following comments from Federal Rese... Full story

Yahoo Finance • 2 months ago

Biggest stock movers Tuesday: SAVA, CLSK, and more

[Abstract Finance Technology Concept] koto_feja Stock futures inched higher Tuesday premarket as major U.S. indexes hit record highs; investors await Fed Chair Powell’s speech. Here are some of Tuesday's biggest stock movers: BIGGEST ST... Full story

Yahoo Finance • 2 months ago

Cassava Sciences CEO buys $534K in company stock

* Cassava Sciences (NASDAQ:SAVA [https://seekingalpha.com/symbol/SAVA]) president & CEO Richard Barry has disclosed [https://seekingalpha.com/filing/10438889]a purchase of 237,941 shares of the company’s common stock in a transaction val... Full story

Yahoo Finance • 4 months ago

Cassava Sciences GAAP EPS of -$0.92

* Cassava Sciences press release [https://seekingalpha.com/pr/20200807-cassava-reports-q2-2025-financials-results-and-provides-business-update] (NASDAQ:SAVA [https://seekingalpha.com/symbol/SAVA]): Q2 GAAP EPS of -$0.92. * Cash and cas... Full story

Yahoo Finance • 4 months ago

Cassava Reports Q2 2025 Financials Results and Provides Business Update

Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced neuroscience leaders to guide the... Full story

Yahoo Finance • 4 months ago

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

Joseph Hulihan, MD, MSHP, brings substantial clinical development experience advancing novel therapies for TSC-related epilepsy and other neurological disordersClinical study for simufilam in TSC-related epilepsy expected to begin in H1 20... Full story

Yahoo Finance • 4 months ago

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Study in a TSC mouse model further demonstrates simufilam’s anti-seizure activityStudy conducted in collaboration with TSC Alliance using a well-accepted Tsc1-knockout modelFirst clinical study for simufilam in TSC-related epilepsy expecte... Full story

Yahoo Finance • 7 months ago

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for c... Full story

Yahoo Finance • 8 months ago

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s diseaseSimufilam continued to demonstrate an overall favorable safety pr... Full story

Yahoo Finance • 9 months ago

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter 2025License agreement brings potential in a new therapeutic application for simufilam for seizure... Full story

Yahoo Finance • 10 months ago

Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAVA

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsui... Full story

Yahoo Finance • 10 months ago

SAVA DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVA

NEW YORK, Feb. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inc... Full story

Yahoo Finance • 10 months ago

SAVA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. (SAVA) Investors of Filing Deadline in Class Action Lawsuit

RADNOR, Pa., Feb. 08, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western... Full story

Yahoo Finance • 10 months ago

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit – SAVA

NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsui... Full story

Yahoo Finance • 10 months ago

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Shareholders

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged... Full story

Yahoo Finance • 10 months ago

SAVA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVA

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inc... Full story

Yahoo Finance • 10 months ago

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassav... Full story